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A B S T R A C T
Quantification of intact proteins in complex biological matrices by liquid chromatography-mass spectrometry
(LC-MS) is a promising analytical strategy but is technically challenging, notably for concentrations at or below
the ng/mL level. Therefore, MS-based protein quantification is mostly based on measuring protein-specific
peptides, so-called ‘surrogate peptides’, that are released through proteolysis. While quantitative protein bioa-
nalysis based on peptide LC-MS is much more sensitive, not every peptide is suitable in this respect. For example,
some peptides are too small to be unique for a protein while others are too large to be measured with sufficient
sensitivity, so careful selection of appropriate peptides is essential. Here we present a validated LC-MS method
for quantification of surfactant protein D (SPD) at clinically relevant levels between 5 and 500 ng/mL using
50 μL of serum. This method targets two SPD-specific peptides in the C-type lectin, ligand binding domain of the
SPD protein. One of these peptides contains a methionine residue which would typically be avoided because of
its unstable nature. Some quantitative methods do target methionine-containing peptides, and corresponding
workflows feature an oxidation step at the peptide level using hydrogen peroxide (H2O2) to convert all me-
thionine residues to more stable methionine sulfoxides. For our method, such a procedure was associated with
peptide loss, hence we developed an oxidation procedure at the protein level using H2O2 to oxidize methionine
residues and the enzyme catalase to quench excess H2O2. This procedure may be applicable to other quantitative
methods based on a surrogate peptide-based approach and may potentially also be useful for MS-based work-
flows targeting intact proteins.
1. Introduction
Over the past decades, mass spectrometry (MS) has emerged as a
robust and versatile analytical platform in the study of proteins [1,2].
MS-based methods can, for example, provide insights into the structure
and composition of these complex biomolecules or can be used to
quantify proteins in a wide range of sample matrices [3]. The latter
application holds considerable potential for addressing key questions in
fundamental research, yet this application is interesting from a clinical
diagnostic point of view as well [4]. However, MS-based protein
quantification is also associated with several challenges and often re-
quires method developers to make an important conceptual decision
upfront, namely whether a protein will be studied in its intact form or
by means of its peptides, which are typically released through proteo-
lysis [5].
Quantitative methods that target protein-specific peptides, so-called
‘surrogate peptides’, represent the vast majority of all targeted pro-
teomics methods, and peptides are furthermore often measured in
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discovery-based proteomics experiments [6–9]. Not every peptide,
however, can be used to identify or quantify a protein of interest. For
example, very small peptides often do not have a unique sequence and
are thus susceptible to interferences, while very large peptides may
suffer from unfavorable analytical behavior (e.g. hydrophobicity-re-
lated peptide adsorption or peak tailing upon reversed-phase liquid
chromatography (LC)) [10,11]. Peptide selection for quantitative
workflows accordingly is a crucial and oftentimes tedious task, and
several critical criteria need to be taken into account [12]. While there
are no consensus criteria for peptide selection, most recommendations
in literature give similar instructions with regard to peptide length,
peptide uniqueness, the absence of post-translational modification
(PTM) sites, proteolytic digestion efficiency, and physicochemical
properties in relation to the MS detection, notably electrospray ioni-
zation (ESI) efficiency and fragmentation upon collision-induced dis-
sociation (CID) [10–14]. Some publications furthermore recommend
avoiding peptides that feature reactive amino acid residues such as
cysteines (oxidation), methionines (oxidation), N-terminal glutamines
(cyclization), and asparagines or glutamines when followed by a gly-
cine (deamidation) [13,14]. Remarkably, only few publications take
genetic variation into account and recommend avoiding peptides that
are prone to modification due to highly prevalent nonsynonymous
single nucleotide polymorphisms (nsSNP) [11–13]. The above-
mentioned set of criteria make it clear that peptide selection can be a
challenging task, and taking all of these criteria into account greatly
reduces the options for studying a protein by means of its proteolytic
peptides. Therefore, strategies are frequently being used to render un-
favorable peptides suitable for LC-MS by modifying their properties
through chemical reactions (e.g. cysteine carbamidomethylation using
iodoacetamide, full methionine oxidation using hydrogen peroxide)
and thereby increasing the options for reliably quantifying a given
protein of interest [15–17].
Surfactant protein D (SPD) is one of the four surfactant proteins
present in human pulmonary surfactant, a complex mixture of lipids
and proteins that covers the respiratory epithelium and maintains a low
surface tension thereby preventing the lungs from collapsing [18].
Moreover, SPD is an important component of the innate immune re-
sponse to various pathogens including bacteria, fungi, and viruses [19].
This protein has been proposed to play a key role in several pulmonary
disorders and is considered to be a promising biomarker for asthma,
chronic obstructive pulmonary disease (COPD), and interstitial lung
disease [20–24]. Its current status as so-called ‘biomarker candidate’ is
based on measurements with a small number of commercial enzyme-
linked immunosorbent assay (ELISA) kits, and corresponding SPD le-
vels, as reported in literature, were found to exhibit considerable var-
iation [25]. The development of SPD as biomarker would thus benefit
from alternative methodologies that generate defined chemical in-
formation rather than measuring SPD indirectly, as is the case for im-
munoassays.
In this study, we developed an LC-MS method for quantification of
SPD in human serum at clinically relevant ng/mL levels and validated
this method following requirements as stipulated in the European
Medicines Agency (EMA) and United States Food and Drug
Administration (FDA) guidelines [26,27]. SPD quantification was based
on a surrogate peptide approach by targeting two tryptic peptides in the
C-type lectin, ligand binding domain of SPD. One of these peptides
contains a methionine residue, which could be readily oxidized to the
sulfoxide by treating samples with H2O2 after tryptic digestion. How-
ever, this procedure gave rise to peptide loss, which was incompatible
with a validated quantitative bioanalytical method. To overcome this
limitation, we developed an oxidation procedure at the protein level
using H2O2 which is followed by an incubation step with catalase to
quench excess H2O2 to arrive at a validated assay for SPD quantifica-
tion.
2. Experimental
2.1. Chemicals and materials
Recombinant human SPD (rh-SPD; Cat. No. 1920-SP; UniProtKB ID
‘P35247’; Ala21-Phe375 with a Glu22Gly substitution) and monoclonal
anti-SPD antibody (Cat. No. MAB1920; clone 292201) were purchased
from R&D Systems (Abingdon, U.K.). Stable-isotope-labelled (SIL) SPD
peptides carrying 13C- and 15N-labelled lysine residues (i.e. NEAAFLS-
MTDSK and SAAENAALQQLVVAK) were synthesized by Thermo
Scientific's Peptide Synthesis Services and were obtained as crude
peptides (≥99% isotopic purity, peptide purity unspecified (un-
purified), not quantified) via Life Technologies Europe B.V. (Bleiswijk,
The Netherlands). Acetonitrile (ACN; LC-MS grade) was obtained from
Biosolve (Valkenswaard, The Netherlands) and sequencing grade
modified trypsin was purchased from Promega (Madison, WI, U.S.A.).
Nunc-Immuno™ MicroWell™ 96 wells plates with MaxiSorp™ coating
(Cat. No. M9410), bovine serum albumin (BSA; Cat. No. A7638), cat-
alase (from bovine liver; 2–5 kU/mg; Cat. No. C9322), hydrogen per-
oxide (H2O2; 30% (w/w) in water; Cat. No. 216763), and phosphate
buffered saline (PBS; 10× ; Cat. No. D1408) as well as all other che-
micals were purchased from Sigma-Aldrich (Zwijndrecht, The
Netherlands).
2.2. Serum samples
Pooled serum from healthy human subjects (obtained from Seralab,
West Sussex, U.K.) was used for preparation of the quality control (QC)
samples. The serum was either used directly as QC-low sample or was
fortified with rh-SPD at two levels to obtain the QC-medium and QC-
high samples. For recovery and spike-recovery experiments, six in-
dividual sources of serum from healthy human subjects were used as
well as a lipemic serum sample (triglyceride content> 150mg/dL) and
a hemolytic sample that was prepared by adding freeze-thawed whole
blood (2%) to serum from a healthy human subject (all from Seralab).
2.3. Calibrants and internal standard
Lyophilized SPD was dissolved in Milli-Q water to obtain a 500 μg/
mL solution (based on the quantity as declared by the supplier, which
was confirmed by quantitative amino acid analysis), which was diluted
to 100 μg/mL with 1×PBS, pH 7.4 (PBS Buffer). The resulting solution
was diluted to 10 μg/mL with 1% BSA in PBS Buffer (Surrogate Matrix),
and calibration samples were prepared at 5, 10, 20, 50, 80, 100, 200,
400, and 500 ng/mL in Surrogate Matrix. The internal standard (IS)
stock solution was prepared by diluting the two SIL-peptides (supplied
as crude solutions in 0.1% trifluoroacetic acid (TFA) in 50% ACN) with
1% dimethyl sulfoxide (DMSO) in water to a 100× stock solution
which, upon dilution in Digestion Buffer (see below), matched the
middle of the calibration curve (approx. 50 ng/mL).
2.4. Antibody-based SPD capture and in-well digestion
The presented method is analogous to a previously published
method featuring a sequential microtiter plate-based immunoaffinity
enrichment and in-well digestion protocol [28], with the exception of a
methionine oxidation step. Briefly, microplate wells were coated
overnight with 0.5 μg of anti-SPD antibody in PBS Buffer, washed with
Wash Buffer (0.05% Tween-20 in PBS Buffer), blocked for 60min with
Blocking Buffer (1% BSA in PBS Buffer), and washed again with Wash
Buffer. Next, 100 μL of Sample Solution (1:1 mixture of serum or cali-
brant and Surrogate Matrix) was added to the wells, and the plates were
incubated for 180min. After washing the wells with Wash Buffer,
100 μL of Digestion Buffer (1× IS stock solution in 100mM ammonium
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bicarbonate (ABC) containing 10mM TCEP) was added to the wells,
plates were sealed, and disulfide bonds were reduced for 30min at
60 °C. After cooling the plates to room temperature, thiols were alky-
lated in 20mM iodoacetamide (IAM) for 30min in the dark after which
non-reacted IAM was quenched with a 0.5 molar equivalent of DTT for
5min. Methionines were subsequently oxidized in 1% hydrogen per-
oxide (H2O2; 5 μL 23% H2O2 in water) for 20min (15min on a plate
shaker (900 RPM) and 5min in a plate centrifuge) at room temperature,
and the excess of H2O2 was afterwards quenched with 0.5 μg catalase
(1–2.5 U; 5 μL 0.1 μg/μL catalase in ABC) by incubation for 55min on a
plate shaker (900 RPM) and 5min in a plate centrifuge at room tem-
perature. Lastly, proteins were digested with 200 ng of trypsin over-
night at 37 °C, and the digests were acidified through addition of formic
acid (FA) after which they were stored in the autosampler of the LC-MS
system at 10 °C until analysis.
2.5. Targeted analysis by LC-MS
Analyses were performed with a Waters Ionkey/MS system using an
ACQUITY M-Class UPLC and a XEVO TQ-S mass spectrometer (Milford,
MA, U.S.A.) operating in the multiple reaction monitoring (MRM)
mode. 15 μL of sample was loaded onto a C18-bonded trap column
(Dionex, Cat. No. 160454) for 2.5min at 20 μL/min with 3% mobile
phase B (0.1% FA in ACN) in mobile phase A (0.1% FA in water).
Trapped peptides were subsequently separated on a C18-bonded iKey
LC column (Waters, Cat. No. 186007261) kept at 40 °C with an 8-min
linear gradient from 3 to 27% B at 3 μL/min, after which the column
was cleaned (1min at 60% B and 5min at 95% B) and equilibrated
(3min at 3% B). MRM transitions and settings for SAAENAALQQLVVAK
and NEAAFLSMTDSK are presented in Table A.1, and specific MS op-
eration conditions have been described in detail elsewhere [28].
2.6. Method validation
The method was validated following requirements as stipulated in
the most recent versions of the EMA and FDA guidelines on bioanaly-
tical method validation [26,27]. Specifically, the following criteria
were addressed: calibration curve, accuracy & precision, recovery, se-
lectivity (e.g. spike recovery), and stability (e.g. 27 days benchtop,
5× freeze-thaw, and 20 days autosampler (10 °C)). Corresponding ex-
perimental procedures have previously been described in detail [28].
2.7. Method comparison and testing
For method comparison, 32 serum samples were analyzed from a
cross-sectional study (NCT00807469) within the University Medical
Center Groningen (UMCG) [29]. This study was ethically approved by
the UMCG's review board (METc 2008/136) and adheres to the De-
claration of Helsinki. Blood samples were collected as described pre-
viously [30]. In all samples, SPD was quantified using the commonly-
used Surfactant Protein D Human ELISA from BioVendor (Cat. No.
RD194059101) as well as the novel LC-MS method. The LC-MS method
was furthermore tested by measuring 179 samples from the above-
mentioned clinical study, of which 32 had already been analyzed for
method comparison purposes. For this work, we also performed in-
curred sample reanalysis on 20 serum samples, which corresponds to
11% of the total number of samples, in agreement with EMA and FDA
recommendations [26,27].
3. Results and discussion
3.1. Method development
We aimed to develop a surrogate peptide-based LC-MS method for
quantification of SPD in human serum at clinically relevant ng/mL le-
vels which employs an external calibration (i.e. using calibration
samples) strategy as well as stable isotope labelled (SIL-)peptides as
internal standards, given that a SIL-version of the full-length SPD pro-
tein was not available. In addition, we aimed to include, at least, two
peptides which may prove valuable in case interferences are en-
countered when applying the method to clinical studies, which feature
samples that are not as ‘predictable’ as the (commercial) sera that are
typically used for method development and method validation pur-
poses. Inspired by the multitude of recommendations for peptide se-
lection [10–14], we furthermore aimed to select peptides that are of
favorable length (7–20 amino acids), lack unfavorable amino acid re-
sidues (carrying post-translational modifications) or sequence motifs
(e.g. deamidation-prone NG and QG sequence motifs, cyclization-prone
N-terminal glutamines), lack highly prevalent nsSNPs, and are unique
for the human SPD protein (Ensembl gene ID ‘ENSG00000133661’).
Only few peptides of the 35 kDa SPD protein meet these criteria when
considering trypsin as well as six alternative proteases (see Figs. A.1
and A.2) [31]. Five tryptic peptides were eventually tested, of which
two, NEAAFLSMTDSK (position 308–319) and SAAENAALQQLVVAK
(position 293–307), were reliably detected in serum. Both of these
peptides are located in the C-type lectin, ligand binding domain of SPD.
The NEAAFLSMTDSK peptide is furthermore expected to be absent in
approximately 1% of the population due to a nsSNP (i.e. rs4469829)
giving rise to a Glu309Lys substitution (based on data from the ExAC
Browser [32]). In subjects carrying this nsSNP, an N-truncated version
of the NEAAFLSMTDSK peptide can be expected which lacks the first
two amino acids. As this nsSNP occurs in only 1% of the population, we
did not focus on this mutation, but the sequence of this truncated
peptide is still unique for the SPD protein, hence it is, in principal,
possible to include it as surrogate peptide.
The NEAAFLSMTDSK peptide contains an oxidation-prone methio-
nine residue which does not necessarily affect its suitability as quanti-
fier peptide. However, we observed peptide loss when applying a
published approach [17] to oxidize methionine residues using hydrogen
peroxide (H2O2) at the peptide level, which may be due to reactive
oxygen species that are formed following the addition of H2O2. We
therefore adopted an H2O2 oxidation step at the protein level directly
followed by H2O2 quenching with catalase, an enzyme that is present in
aerobic organisms and that catalyzes the dismutation of two H2O2
molecules into oxygen and water. SPD denaturation prior to the oxi-
dation step was needed in order to fully oxidize Met315 at the protein
level (see Fig. A.3). In addition, we needed to optimize the duration of
the oxidation step as well the percentage of H2O2 that was used (see Fig.
A.4). We furthermore increased the rotation speed and introduced in-
termediate centrifugation steps for both the oxidation and the H2O2
quenching procedures in order to remove oxygen bubbles from the
sample solution (see the Experimental section for the final procedure).
Lastly, we verified the relevance of the H2O2 quenching step (see Fig.
A.5) prior to validating the method according to regulatory guidelines.
3.2. Method validation
Table 1 summarizes the validation results. A full overview of all
validation results is provided in Tables A.2 to A.21. The LC-MS method
for SPD quantification based on a surrogate peptide approach was va-
lidated following requirements as stipulated in the most recent versions
of the EMA and FDA guidelines on bioanalytical method validation
[26,27]. This method employs an adsorptive microtiter plate-based
immunoaffinity enrichment procedure for which we demonstrated that
using 0.5 μg of antibody per sample allowed for the enrichment of SPD
from 50 μL of human serum (see antibody titration results in Fig. A.6)
with good precision (< 10%; see Tables A.2 and A.3). Accurate SPD
quantification was furthermore shown for a 1/x-weighted linear cali-
bration model using 9 non-zero calibrants with recombinant human
SPD (rh-SPD) levels ranging from 5 to 500 ng/mL (see Tables A.4 and
A.5 as well as Fig. A.7 which features typical examples of chromato-
grams for the 5 ng/mL calibration samples). For preparation of the
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calibrants, 1% bovine serum albumin (BSA) in phosphate-buffered
saline (PBS) was used as surrogate matrix. This matrix was found to
adequately mimic human serum with regard to the enrichment of rh-
SPD and the subsequent sample preparation procedures (see the re-
sponses and overlapping 95% confidence intervals for the slopes of
‘Human Serum’ and ‘1% Bovine Serum Albumin’ in Fig. A.8).
Evaluation of accuracy and precision revealed acceptable biases and
CVs (within± 20%) for the lower limit of quantification sample (LLOQ;
see Tables A.6 and A.7) as well as acceptable biases and CVs
(within±15%) for the QC-low, QC-medium, and QC-high samples (see
Tables A.8 to A.13). Acceptable biases and CVs (within± 15%) were
also observed for all stability assessments (see Tables A.14 to A.19)
which indicates that SPD is a rather stable protein, at least based on the
site that is recognized by the anti-SPD antibody and the two surrogate
peptides that are used for SPD quantification.
Selectivity was assessed on the basis of spike recovery experiments
which were carried out on six different sources of human serum, a li-
pemic sample, and a hemolytic sample. These experiments resulted in
recoveries close to 100% except for the lipemic sample which featured a
recovery of 71–73% (see Tables A.20 and A.21). Interpretation of these
results should be done prudently as corresponding spiking procedures
were carried out using rh-SPD. This surrogate protein calibrator may
not fully reflect the heterogeneity of circulating SPD forms (so-called
proteoforms [33] or protein species [34]) thus potentially leading to
variance in immunoaffinity enrichment and digestion efficiencies. In
addition, it should be taken into account that circulating SPD mainly
originates from the lungs and leaks out from lung compartments into
the circulation [35,36]. The corresponding uptake (mechanism and
efficiency) of endogenous SPD in blood may be different from the up-
take of recombinant SPD in serum during the spike recovery experi-
ments, which represents another potential explanation for deviating
spike recovery results that needs to be addressed in further studies.
3.3. Method comparison
The LC-MS method for SPD quantification was compared with an
ELISA, which is registered in the European Union for in vitro diagnostic
(IVD) use, on the basis of 32 human serum samples [29]. This com-
parison revealed good correlation between the methods (R2= 0.9) but
indicated also that the LC-MS method yields approximately 1.5 times
higher SPD levels than the ELISA (see Fig. 1). As most of the samples
included in this comparison are pairs of samples from different time
points belonging to the same patients, we were also able to compare
both methods on the basis of the ratio of SPD levels for these sample
pairs (N=14). Again, correlation between the methods was good
(R2= 0.9) (see Fig. A.9). Since both methods were referenced against
the same SPD protein standard and because all measured SPD levels
were within the linear range of the ELISA's calibration curve, it is likely
that the observed 1.5-fold difference is related to the different detection
principles of the assays, for example, due to varying specificities and/or
binding efficiencies of the antibody that is used for the LC-MS method
and those that are used by the ELISA (binding sites of the antibodies are
unknown). In addition, it should be taken into account that the ELISA
measures intact SPD while the LC-MS method includes a proteolytic
digestion step and analyzes SPD by means of tryptic peptides, which
represent two fundamentally different approaches to quantify a protein
of interest.
A comparison between the detection principles of the assays is not
straightforward, or feasible, as the ELISA relies on a secondary detec-
tion antibody to bind SPD proteins in order to generate a signal, while
the LC-MS method detects and quantifies SPD based on protein-specific
surrogate peptides. We were, however, able to make a (preliminary)
comparison between the capturing steps of both methods by analyzing
6 human serum samples and two calibration standards with the vali-
dated LC-MS method as well as with a modified version of this method
in which we used the BioVendor ELISA plate for immunoaffinity en-
richment and in-well digestion prior to LC-MS. This experiment re-
vealed a very good correlation between both approaches (R2≥0.98;
see Fig. A.10) suggesting that both methods capture a comparable
fraction of SPD proteoforms. Nevertheless, the evidence to support this
conclusion is circumstantial, and the exact nature of the observed bias
between both methods has yet to be determined.
The concept of providing a mass spectrometric readout for a com-
mercial ELISA kit was furthermore adopted for a data-dependent ac-
quisition (DDA) shotgun proteomics experiment (see Method A.1). Here
we attempted to identify SPD and potentially also detect SPD peptides
carrying posttranslational modifications, such as hydroxylated proline
or lysine residues in the N-terminal, collagen-like domain of the pro-
tein. We furthermore searched for SPD peptide sequences that feature
substituted amino acid residues due to one of the five most prevalent
nsSNPs that are listed in the ExAC Browser [32], namely rs2243639
(Thr180Ala, AF=0.66), rs721917 (Met31Thr, AF=0.47), rs3088308
(Ser290Thr, AF= 0.09), rs17878336 (Leu123Val, AF=0.03), and
rs4469829 (Glu309Lys, AF= 0.01). Based on four human serum
Table 1
Summary of validation data a.
NEAAFLSMTDSK SAAENAALQQLVVAK
max. CV max. biasb max. CV max. biasb
calibration curve (5 runs, 9 non-zero calibrants) 7% 4% 7% 4%
accuracy & precision (3 runs, in 6-fold) LLOQ 20% 19% 14% −12%
QC-low 8% 13% 6% 10%
QC-medium 11% 2% 14% (−)3%
QC-high 5% 6% 4% 3%
autosampler stability 10 °C (20 days, in 3-fold) 6% −12% 9% −13%
bench-top stability (27 days, in 3-fold) 9% −12% 4% −13%
freeze-thaw stability −20 °C (5 cycles, in 3-fold) 5% 14% 7% 9%
NEAAFLSMTDSK SAAENAALQQLVVAK
recovery CV bias recovery CV bias
recovery (6 different serum samples) 76% 7% – 78% 9% –
spike recovery (6 different serum samples) 95% 14% −5% 99% 15% −1%
lipemic sample spike recovery (in 2-fold) 71% – −29% 73% – −27%
hemolytic sample spike recovery (in 2-fold) 98% – −2% 96% – −4%
a An extensive summary of the validation results is presented in Tables A.2 to A.21.
b The average value of measured concentrations during the accuracy and precision experiments was used as nominal concentration for the accuracy and precision
experiments (QC-low, QC-medium, and QC-high) and the stability assessments.
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samples and by using two different proteases, we identified SPD in all
samples, detected hydroxylated proline residues in two samples, and
obtained mass spectrometric evidence for the presence of two nsSNPs
(i.e. rs721917, rs3088308) in one sample (see Figs. A.11 and A.12).
These experiments and corresponding findings highlight the scope
of this method and other surrogate peptide-based LC-MS methods. This
direction is instigated by the remarkable (and still improving) speed
and sensitivity of modern mass spectrometers. These instruments can,
on the one hand, be used to provide a protein quantity and, on the other
hand, may yield structural information of a protein target of interest,
which represents a distinct characteristic of MS-based assays as com-
pared to conventional immunoassays.
3.4. Method testing
The LC-MS method was applied to 179 clinical samples [29] (ana-
lysis and interpretation of the clinical data will be reported in future
publications) in order to study the method's performance further. These
analyses showed that the method features excellent inter-peptide
agreement (see Fig. 2 and Fig. A.13) thereby supporting the initial
peptide comparison data that were obtained during the method com-
parison experiment (see the plots on the right in Fig. 1A and B). We
furthermore performed incurred sample reanalysis according to EMA
and FDA recommendations [26,27] to verify the reliability of the re-
ported SPD levels. These experiments revealed that 80% and 85% of the
repeat analyses for SAAENAALQQLVVAK and NEAAFLSMTDSK, re-
spectively, yielded SPD levels with a relative difference within± 20%
Fig. 1. Comparisons between the quantitative LC-MS SPD method (both the NEAAFLSMTDSK and the SAAENAALQQLVVAK peptides) and the BioVendor Surfactant
Protein D Human ELISA (Cat. No. RD194059101) using (A) linear regression and (B) Bland-Altman plots.
Fig. 2. Comparisons between SPD levels calculated on the basis of the tryptic
SPD peptides NEAAFLSMTDSK and SAAENAALQQLVVAK using linear regres-
sion. The corresponding Bland-Altman plot is shown as Fig. A.13.
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(see Fig. A.14). These percentages are well above the 67%, which is
specified as cut-off value for chromatographic assays in the EMA and
FDA guidelines [26,27] and thus underline the adequate performance
of the presented SPD method.
4. Conclusion
We describe a surrogate peptide-based LC-MS method for quantifi-
cation of SPD in human serum which complies with current interna-
tional guidelines on bioanalytical method validation. The method
shows good correlation and agreement with an IVD-grade ELISA kit,
however, the LC-MS method reports approximately 1.5 times higher
SPD levels compared to the ELISA. The exact reasons for this difference
are still unclear, yet the difference may be related to the fact that the
ELISA measures intact SPD, while the LC-MS method analyzes the SPD
protein by means of two tryptic peptides. It could, for example, be
possible that the secondary, detection antibody of the ELISA is ham-
pered by interactions between SPD and (some of) its protein binding
partners, whereas such interactions are not expected to interfere with
the LC-MS method due to inclusion of a trypsin digestion step.
A distinctive feature of the LC-MS method is the incorporation of an
H2O2-based methionine oxidation step at the protein level followed by
incubation with the enzyme catalase to quench excess H2O2. This
combination may provide a useful alternative to conventional H2O2-
based methionine oxidation procedures at the peptide level, in case
such procedures give rise to peptide stability issues. In addition, this
procedure may potentially be valuable for MS-based workflows tar-
geting intact proteins. However, it must be kept in mind that protein
size and three-dimensional structure need to be considered in light of
the effectiveness of oxidation procedures at the protein level.
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